For decades, value-based pricing has been the holy grail of diagnostics. In therapeutics and other medical products, pricing linked to outcomes, clinical impact, and downstream cost savings is now well established. In diagnostics, reimbursement has remained largely anchored to cost-based fee schedules that reward test execution rather than clinical value. That model is starting to show its limits.
Today, there are a small but growing number of CPT and PLA codes that command reimbursement of $5,000 or more. What is striking is not just the dollar amount, but the pattern. Nearly all of these high-value codes are tied to single-site or highly centralized specialty laboratories, most often in oncology, with a small number of similarly structured non-oncology exceptions. That concentration is not accidental. It reflects the narrow set of conditions under which premium diagnostic pricing is currently achievable.
Single-site specialty labs such as Natera, Guardant Health, and others have broken through traditional reimbursement ceilings by tightly coupling proprietary assays with focused indications, strong clinical utility, and disciplined evidence generation. These tests influence treatment decisions, change care pathways, and credibly claim downstream cost and outcome impact.
The operating model matters as much as the assay. Centralization enables consistent test performance, rapid iteration, and deep investment in clinical studies. It also makes the value story auditable and contained. Pricing power is concentrated because the assay, the lab, and the interpretation are inseparable, which appears to matter in an environment where payers remain cautious about utilization risk.
Abbott’s acquisition of Exact Sciences reinforces this point. The deal signals confidence not just in molecular screening, but in a lab-centered model where premium diagnostics can be paired with scale, evidence, and longitudinal patient engagement. High-value, centralized diagnostics are no longer fringe exceptions, but strategically relevant assets even for large IVD manufacturers.
At the same time, this model exposes its limits. Single-site specialization is not a universal solution. Most reimbursement frameworks remain cost-anchored, coding systems lag innovation, and payers resist broad outcomes-linked pricing without narrowly defined populations and decision points. As a result, value-based pricing remains the exception and is difficult to standardize across decentralized testing environments.
Seen this way, single-site specialty labs are not the end state of value-based diagnostics, but a policy-compatible workaround. They show what is possible when evidence, scale, and clinical relevance align within a tightly controlled structure. They also reveal how constrained the reimbursement architecture still is.
Diagnostics can clearly create value. The harder problem is that the system has not yet learned how to consistently pay for it.
